Clearstead Advisors
SKYE icon

Clearstead Advisors’s Skye Bioscience SKYE Stock Holding History

Clearstead Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$51 – 3277
2025
Q2 		$51 Buy
+2
New +$33 ﹤0.01% 2668

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Clearstead Advisors's SKYE Position: Q3 2025 in Review

Clearstead Advisors sold out of Skye Bioscience (SKYE) in Q3 2025, closing a stake of 2 shares — an estimated $51 sold.

Clearstead Advisors first reported a position in SKYE in Q2 2025 and held it in 1 quarter. The position peaked at $51 in Q2 2025. 52 funds tracked by Wall St. Rank hold SKYE as of Q3 2025.

  • Clearstead Advisors reported no remaining Skye Bioscience position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 2 Skye Bioscience shares in Q3 2025, an estimated $51.
  • Clearstead Advisors first reported a position in Skye Bioscience in Q2 2025 and held it in 1 quarter.
  • Clearstead Advisors's Skye Bioscience position peaked at $51 in Q2 2025.
  • 52 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.